Literature DB >> 8755487

Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit.

K Ohno1, H L Wang, M Milone, N Bren, J M Brengman, S Nakano, P Quiram, J N Pruitt, S M Sine, A G Engel.   

Abstract

We describe the genetic and kinetic defects for a low-affinity fast channel disease of the acetylcholine receptor (AChR) that causes a myasthenic syndrome. In two unrelated patients with very small miniature end plate (EP) potentials, but with normal EP AChR density and normal EP ultrastructure, patch-clamp studies demonstrated infrequent AChR channel events, diminished channel reopenings during ACh occupancy, and resistance to desensitization by ACh. Each patient had two heteroallelic AChR epsilon subunit gene mutations: a common epsilon P121L mutation, a signal peptide mutation (epsilon G-8R) (patient 1), and a glycosylation consensus site mutation (epsilon S143L) (patient 2). AChR expression in HEK fibroblasts was normal with epsilon P121L but was markedly reduced with the other mutations. Therefore, epsilon P121L defines the clinical phenotype. Studies of the engineered epsilon P121L AChR revealed a markedly decreased rate of channel opening, little change in affinity of the resting state for ACh, but reduced affinity of the open channel and desensitized states.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755487     DOI: 10.1016/s0896-6273(00)80289-5

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  83 in total

Review 1.  Inherited and experimentally induced changes in gating kinetics of muscle nicotinic acetylcholine receptor.

Authors:  C Bouzat; F J Barrantes
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

2.  The effects of non-identifiability on testing for detailed balance in aggregated Markov models for ion-channel gating.

Authors:  M Wagner; J Timmer
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

3.  Kinetic determinants of agonist action at the recombinant human glycine receptor.

Authors:  Trevor M Lewis; Peter R Schofield; Annette M L McClellan
Journal:  J Physiol       Date:  2003-04-04       Impact factor: 5.182

4.  Mutation in the M1 domain of the acetylcholine receptor alpha subunit decreases the rate of agonist dissociation.

Authors:  H L Wang; A Auerbach; N Bren; K Ohno; A G Engel; S M Sine
Journal:  J Gen Physiol       Date:  1997-06       Impact factor: 4.086

5.  Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit.

Authors:  M Milone; H L Wang; K Ohno; T Fukudome; J N Pruitt; N Bren; S M Sine; A G Engel
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

6.  Myasthenic syndrome AChRα C-loop mutant disrupts initiation of channel gating.

Authors:  Xin-Ming Shen; Joan M Brengman; Steven M Sine; Andrew G Engel
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

7.  Plasticity of acetylcholine receptor gating motions via rate-energy relationships.

Authors:  Ananya Mitra; Richard Tascione; Anthony Auerbach; Stuart Licht
Journal:  Biophys J       Date:  2005-08-19       Impact factor: 4.033

Review 8.  Congenital Myasthenic Syndromes: a Clinical and Treatment Approach.

Authors:  Constantine Farmakidis; Mamatha Pasnoor; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Treat Options Neurol       Date:  2018-07-21       Impact factor: 3.598

9.  Aromatic Residues {epsilon}Trp-55 and {delta}Trp-57 and the Activation of Acetylcholine Receptor Channels.

Authors:  Pallavi A Bafna; Archana Jha; Anthony Auerbach
Journal:  J Biol Chem       Date:  2009-01-26       Impact factor: 5.157

10.  Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors.

Authors:  Tse-Yu Wu; Caleb M Smith; Steven M Sine; Mark M Levandoski
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.